Chronic Enteropathy refers to long-term inflammatory disorders of a dog's gastrointestinal tract, identified by persistent clinical signs lasting over 3 weeks, with other non-GI causes excluded.

Food-responsive enteropathies are identified as the most prevalent, accounting for 50 to 65% of cases in dogs.

INTESTINAL ULTRACARE LOW FAT

Based on a study at Cornell University College of Veterinary Medicine, Farmina formulated a new diet that specifically addresses Chronic Enteropathies.



INDICATIONS OF USE

Canine chronic enteropathy Reduction of intestinal absorptive disorders Compensation for maldigestion Exocrine pancreatic insufficiency (EPI)



1.5 kg - 10 kg



Hydrolyzed fish protein as a sole protein source

Lower fat conten

from fish oil

Cobalamin and

folate integration





With prebiotics, FOS, MOS



electrolyte integration



digestible

Join the Vet Portal, many advantages for you!

- Special Offers: Enjoy up to 35% off on Farmina products for you and your staff's pets.
- Loyalty Program for you: Earn blue credits through product recommendations and enjoy various benefits.
- Digital prescription: immediate advantages for your customers thanks to a voucher discount on the first purchase.
- · Product Updates: Stay informed about new products.
- Latest Research Access: Exclusive access to Farmina's veterinary studies and research documents.

Additional advantages for your customer



Up to 150€* savings: by joining the yearly plan your customer can access special offers and discounts.



Genius Rewards: the program to prize your loyalty.

scan the Qr-code and download the article




Farmina Genius Support: Expert advice for your clients with a dedicated









Bibliography:

- · Aarti Kathrani, Dietary and Nutritional Approaches to the Management of Chronic Enteropathy in Dogs and Cats, Vet Clin Small Anim, 2021; 51(1): 123-136,
- Marc Myers, Stephen A. Martinez, Jonathan T. Shiroma, Adam T. Watson, Roger A. Hostutler; Prospective Evaluation of Low-Fat Diet Monotherapy in Dogs with Presumptive Protein-Losing Enteropathy. J Am Anim Hosp Assoc 1 March 2023; 59 (2): 74-84.
- Allenspach K, Rizzo J, Jergens AE, Chang YM. Hypovitaminosis D is associated with negative outcome in dogs with protein losing enteropathy: a retrospective study of 43 cases. BMC Vet Res. 2017;13:96.
- Allenspach K, Wieland B, Grone A, et al. Chronic enteropathies in dogs: evaluation of risk factors for negative outcome. J Vet Intern Med. 2007;21:700-708.
- Batt RM, Morgan JO. Role of serum folate and vitamin B12 concentrations in the differentiation of small intestinal abnormalities in the dog. Res Vet Sci. 1981;32(1):17-22.
- Craven M, Simpson JW, Ridyard AE, Chandler ML. Canine inflammatory bowel disease: retrospective analysis of diagnosis and outcome in 80 cases (1995-2002). J Small Anim Pract. 2004;45:336-342.
- Dandrieux JR, Martinez Lopez LM, Prakash N, Mansfield CS. Treatment response and long term follow up in nineteen dogs diagnosed with chronic enteropathy in Australia. Aust Vet J. 2019;97:301-307.
- Dandrieux JRS, Mansfield CS. Chronic enteropathy in canines: prevalence, impact and management strategies. Vet Med. 2019;10: 203-214.
- German AJ, Day MJ, Ruaux CG, Steiner JM, Williams DA, Hall EJ. Comparison of direct and indirect tests for small intestinal bacterial overgrowth and antibiotic-responsive diarrhea in dogs. J Vet Intern Med. 2003;17[1]:33-43.

- Jablonski-Wennogle SA, Stockman J, Webb CB. Prospective evaluation of a change in dietary therapy in dogs with steroidresistant protein-losing enteropathy. J Small Anim Pract. 2021;62:756-764.
- Marchesi MC, Timpano CC, Busechian S, et al. The role of diet in managing inflammatory bowel disease affected dogs: a retrospective cohort study on 76 cases. Vet Ital. 2017;6:297-302.
- Okanishi H, Yoshioka R, Kagawa Y, Watari T. The clinical efficacy of dietary fat restriction in treatment of dogs with intestinal lymphangiectasia. J Vet Intern Med. 2014;28:809-817.
- Rudinsky AJ, Rowe JC, Parker VJ. Nutritional management of chronic enteropathies in dogs and cats. J Am Vet Med Assoc. 2018;253(5): 570-578.
- Schmitz SS, Gow A, Bommer N, et al. Diagnostic features, treatment, and outcome of dogs with inflammatory proteinlosing enteropathy. J Vet Intern Med. 2019;33:2005-2013.
- Simpson KW, Jergens AE. Pitfalls and progress in the diagnosis and management of canine inflammatory bowel disease. Vet Clin North Am Small Anim Pract. 2011;41(2):381-398.
- Simpson, K. W., Miller, M. L., Loftus, J. P., Rishniw, M., Frederick, C. E., & Wakshlag, J. J. (2023). Randomized controlled trial of hydrolyzed fish diets in dogs with chronic enteropathy. Journal of veterinary internal medicine, 10.1111/jvim.16844. Advance online publication.
- Toresson L, Steiner JM, Suchodolski J, et al. Oral cobalamin supplementation in dogs with chronic enteropathies and Hypocobalaminemia. J Vet Intern Med. 2016;30:101-107.





DIETARY MANAGEMENT OF CHRONIC ENTEROPATHIES IN DOGS



www.farmina.com

Total value calculated on a yearly plan of 12 bags of Vet Life Intestinal UltraCare 10kg which participated to Genius Reward getting 1 bag for free.

Choosing quality over quantity: assessing the impact of limited ingredient diets in canine CE


A Novel Dietary Approach to Chronic Enteropathy Management

Chronic enteropathy diagnosis


Chronic enteropathy is defined by:

- The presence of clinical signs of gastrointestinal disease for >3 weeks.

 Pingrestic evaluation consisted of
- Diagnostic evaluation consisted of history, physical examination, CBC, biochemistry profile, baseline serum cortisol concentration, urinalysis, fecal
- examination, and serum cobalamin, and folate concentrations.
- Abdominal ultrasonography, endoscopy, intestinal biopsy, and measurement of trypsin-like immunoreactivity, performed at the discretion of the attending clinician.



No differences in the age, sex, Canine Chronic Enteropathy Clinical Activity Index (CCECAI), or serum concentrations of cobalamin and folate among groups at the time of enrollment.



Clinical response to diet

The response was evaluated after 2 WKS of feeding and determined by clinical improvement.

NON-PLE DOGS GROUP

DIET	HF n = 7	HF + n = 9	CONTROL n = 7
RESPONSE			
to initial diet (12 wks)	7/7 3	6/9 1_	6/7
to final diet (12 wks)	10/10	7/10	6/7
sustained (26 wks)	7/7	7/7	4/4

Five dogs were lost to follow-up for various reasons:

- · 2 dogs were euthanized due to non-gastrointestinal diseases.
 - n-gastrointestinal diseases. 1 dog: lost owners contacts
- · 1 dog was re-homed. · 1 dog had behavior issues.

 $\label{lem:continuous} \mbox{ Diet as monotherapy was associated with marked decreases in {\tt CCECAI} \ and \ fecal \ scores. }$

PLE dogs group

One of the two subjects was withdrawn for inappetence 3 weeks after the crossing over.

DIET	HF n =5	HF n = 3	
RESPONSE			
to initial diet (12 wks)	5/5 2	1/3	
to final diet (12 wks)	6/7	1/3	
sustained (26 wks)	6/6	1/1	

Serum analysis

Serum cobalamin

No significant baseline difference Higher at 12 wks than baseline Maintained by diet

			Serum cobalamin (pg/ml)		
Group	Diet	N	Baseline	12 weeks*	Delta
Non-PLE	Control	6	565 (149-1176)	688 (554-1001)	177 (611 to 852)
	HF	7	275 (183-1001)	473 (251-1373)	74 (386 to 789)
	HF+	9	619 (237-969)	853 (669-1908)**	335 (83 to 1640)

Note: Data shown as median (range). Delta = 12 weeks-baseline. *P < .05 12 weeks vs baseline. **P < .05 vs HF at 12 weeks.

Serum folate

Within the normal range at baseline Significantly lower at 6 wks than Restored by the enriched diets in all but 2 dogs baseline

			Foliato (markes))	
			Folate (pg/ml)	
Group	Diet batch A	N	Baseline	Post-diet A*
Non-PLE	Control	5	14.9 (8.67-21.9)	4.29 (2.98-5.14)
	HF	5	7.53 (4.85-19.2)	3.17 (2.22-6.47)
	HF+	4	13.15 (6.9-17.9)	6.5 (2.7-11.9)
PLE	HF	4	10.35 (8.47-12.5)	4.67 (2.96-8.69)
	HF+	0	NA	NA
Group	Diet batch B		Folate (pg/ml)	
		N	Baseline	12 weeks diet B
Non-PLE	Control	1	11.2 (11.2-11.2)	13.8 (13.8-13.8)
	HF	2	10.62 (6.33-14.9)	19 (13-25)
	HF+	6	13.45 (6.55-23.2)	15.25 (11.9-20.7)
PLE	HF	0	NA	NA
	HF+	1	24 [24-24]	6.85 (6.85-6.85)

Note: Data shown as median (range). Diet batch A: Folic acid 0.3 mg/kg (control) and 0.45 mg/kg (HF, HF+); Diet batch B: Folic acid 5 mg/kg (control, HF, HF+).

*P < .05 vs baseline for all diets.

Conclusions

- Long-term clinical remission can be achieved in dogs with CE and a subset of those with PLE by transitioning to a limited ingredient diet
- The response seems to be more related to the ingredient restriction rather than targeting immunogenic antigens.
- Higher inclusion of B-vitamins in the diet can effectively increase and normalize serum concentrations of cobalamin and folate in dogs with CF.
- Fish-based hydrolyzed diets have shown promise in supporting clinical recovery and remission in dogs with PLE.

